The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2026 | Community lymphoma management: which patients should be prioritized for specialist referral?
Nirav Niranjan Shah, MD, Medical College of Wisconsin, Milwaukee, WI, discusses the importance of referral decisions in lymphoma management. While most patients are effectively treated in the community setting, Dr Shah emphasizes that those who experience early relapse or disease progression often have a poorer prognosis and may benefit from consultation with a lymphoma specialist. This interview took place at the 14th Annual Meeting of the Society of Hematologic Oncology (SOHO 2026) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think that the community does a fantastic job in the frontline management of lymphoma. And really, I would argue almost all types of lymphoma. But when you have those lymphoma patients, and sort of let’s be disease agnostic, that relapse early, it doesn’t really matter what the disease is, whether it’s DLBCL or mantle cell or even CLL, early relapsing patients just from a biological disease standpoint tend to have a worse prognosis...
I think that the community does a fantastic job in the frontline management of lymphoma. And really, I would argue almost all types of lymphoma. But when you have those lymphoma patients, and sort of let’s be disease agnostic, that relapse early, it doesn’t really matter what the disease is, whether it’s DLBCL or mantle cell or even CLL, early relapsing patients just from a biological disease standpoint tend to have a worse prognosis. And I think those are patients that deserve an opportunity to potentially meet with a lymphoma expert to talk about what might be the best treatment sequencing for that early relapsing disease. So, I would say that if you have a patient who has a great response and years go by, to keep doing what you’re doing. But if you have a patient that you give with DLBCL or mantle cell or any lymphoma that has early progression of disease, I think it’s reasonable to refer them to a doctor like me or many others like me and have a conversation about what new options may be available to overcome some aggressive biology of the disease.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
